Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Charles River Laboratories International, Inc.

Market Cap 903.19Cr 780.09Cr 718.85Cr 672.88Cr 1.26TCr 86TCr 1.28TCr 8.49TCr 3.31TCr 42TCr 3.39TCr 3.32TCr 1,44700Cr P/E Ratio 2026 *
30.6x
P/E Ratio 2027 * 20.4x
Enterprise Value 1.08TCr 936.62Cr 863.09Cr 807.9Cr 1.51TCr 1,03100Cr 1.54TCr 10TCr 3.97TCr 50TCr 4.07TCr 3.98TCr 1,73700Cr EV / Sales 2026 *
2.81x
EV / Sales 2027 * 2.68x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 905.84Cr
-0.35%+0.97%-15.96%-12.73% 4.3TCr
+3.11%+3.11%+274.29%+507.94% 3.17TCr
+0.22%-1.08%+14.03%-14.37% 3.02TCr
+1.62%-2.08%-4.36%+24.05% 2.89TCr
+4.09%+0.93%+10.83%+18.78% 2.39TCr
-1.63%+2.88%+53.73%+114.36% 1.36TCr
+1.14%+3.62% - - 1.34TCr
-0.40%-1.29%+6.06%+7.59% 1.3TCr
-0.74%-1.62%+105.71%+76.01% 1.22TCr
Average +0.71%+1.45%+55.54%+90.21% 2.33TCr
Weighted average by Cap. +0.98%+1.44%+54.32%+95.99%

Financials

2026 *2027 *
Net sales 385.46Cr 332.92Cr 306.79Cr 287.17Cr 538.17Cr 37TCr 546.5Cr 3.62TCr 1.41TCr 18TCr 1.45TCr 1.42TCr 62TCr 392.38Cr 338.9Cr 312.29Cr 292.32Cr 547.83Cr 37TCr 556.31Cr 3.69TCr 1.44TCr 18TCr 1.47TCr 1.44TCr 63TCr
Net income 29Cr 25Cr 23Cr 21Cr 40Cr 2.71TCr 40Cr 267.96Cr 104.47Cr 1.32TCr 107.01Cr 104.73Cr 4.57TCr 42Cr 36Cr 33Cr 31Cr 58Cr 3.97TCr 59Cr 392.11Cr 152.88Cr 1.93TCr 156.59Cr 153.25Cr 6.68TCr
Net Debt 181.23Cr 156.53Cr 144.24Cr 135.02Cr 253.03Cr 17TCr 256.95Cr 1.7TCr 664.05Cr 8.38TCr 680.16Cr 665.68Cr 29TCr 146.8Cr 126.79Cr 116.84Cr 109.36Cr 204.96Cr 14TCr 208.13Cr 1.38TCr 537.88Cr 6.79TCr 550.93Cr 539.2Cr 24TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
187.51USD
Average target price
212.27USD
Spread / Average Target
+13.20%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!